Advertisement
Original report| Volume 3, ISSUE 3, P153-156, March 1999

Download started.

Ok

Antimicrobial resistance among community-acquired pneumonia isolates in Europe: First results from the SENTRY antimicrobial surveillance program 1997

Open ArchiveDOI:https://doi.org/10.1016/S1201-9712(99)90037-1
Antimicrobial resistance among community-acquired pneumonia isolates in Europe: First results from the SENTRY antimicrobial surveillance program 1997
Previous ArticleSevere pneumococcal infection at a Thai hospital
Next ArticleAmphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Objective: The SENTRY antimicrobial surveillance program was established to monitor the occurrence and antimicrobial susceptibility of bacterial pathogens via an international network of sentinel hospitals.
      Material and Methods: Microorganisms were forwarded to the reference laboratory for testing against various antimicrobial agents using broth microdilution. Twenty European hospitals referred 286 Streptococcus pneumoniae, 309 Haemophilus influenzae, and 167 Moraxella catarrhalis isolates during the first 10 months of the study, starting in April 1997.
      Results: Seven percent of the S. pneumoniae isolates were highly resistant to penicillin, and 21 % showed intermediate resistance. The highly resistant pneumococcal isolates came from Coimbra, Barcelona, Athens, and London, whereas the intermediate penicillin-resistant isolates were received from all participating countries. The incidence of intermediate penicillin-resistant pneumococci was lowest in Lausanne, Freiburg and Duesseldorf, London, and Utrecht and highest in southern European countries. Fifty-five percent of the penicillin-resistant S. pneumoniae were also resistant to erythromycin, and 35% to clindamycin. Sparfloxacin, trovafloxacin, levofloxacin, and vancomycin were fully active against pneumococcal isolates. Haemophilus influenzae isolates were generally highly susceptible to most of the antibiotics tested, and 92% of the M. catarrhalis isolates were resistant to penicillin. Susceptibility to cephalosporins, ciprofloxacin, levofloxacin, and rifampicin was 100%.
      Conclusion: Penicillin may no longer be the first-choice drug for empirical treatment of pneumococcal infections. The newer fluoroquinolones may play a role in the empirical treatment of community-acquired pneumonia.

      Keywords

      References

        • Turner-Warwick M.
        • Hodson M.E.
        • Corrin B.
        • Kerr I.H.
        Clinical atlas of respiratory diseases.
        Gower Medical Publishing, London1990
        • Skudlarska B.A.
        • Scott G.C.
        The role of antibiotics in the management of acute exacerbations of chronic bronchitis (answers to some commonly asked questions).
        Mol Med. 1992; 89: 289-293
        • Ball P.
        • Harris J.M.
        • Lowson D.
        • Tillotson G.
        • Wilson R.
        Acute infective exacerbations of chronic bronchitis.
        QJM. 1995; 88: 61-68
        • Woodhead M.A.
        • Macfarlane J.T.
        • McCracken J.S.
        • Rose D.H.
        • Finch R.G.
        Prospective study of the aetiology and outcome of pneumonia in the community.
        Lancet. 1987; i: 671-674
        • Marston B.J.
        • Plouffe J.F.
        • Breiman R.E.
        • et al.
        Preliminary findings of a community-based pneumonia incidence study.
        in: Breiman R.F. Barbaree J.M. Dufour A.P. Legionella. Proceedings of the Fourth International Symposium of the American Society for Microbiology, Washington, DC1993
        • Research Committee of the British Thoracic Society and Public Health Laboratory Service
        Community-acquired pneumonia in adults in British hospitals in 1982–1983: a survey of aetiology, mortality, prognostic factors, and outcome.
        QJM. 1987; 62: 195-220
      7. MMWR Morb Mortal Wkly Rep. 1995; 44: 535-537
        • Richard M.P.
        • Gil Aguado A.
        • Mattina R.
        • Marre A.
        • SPAR Study Group
        Sensitivity to sparfloxacin and other antibiotics of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis strains isolated from adult patients with community-acquired lower respiratory tract infections: a European multicentre study.
        J Antimicrob Chemother. 1998; 41: 207-214
        • Felmingham D.
        • Grüneberg R.N.
        • Alexander Project Collaborative Group
        A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992–1993: the Alexander Project.
        J Antimicrob Chemother. 1996; 38: 1-57
        • National Committee for Clinical Laboratory Standards
        Performance standards for antimicrobial susceptibility testing. Supplement tables.
        in: NCCLS, Wayne, PA1998: M100-S108
        • Grüneberg R.N.
        • Felmingham D.
        • Alexander Project Group
        Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens.
        Diagn Microbiol Infect Dis. 1996; 25: 169-181
        • Jones R.N.
        • Cormican M.G.
        • Wanger A.
        Clindamycin resistance among erythromycin-resistant Streptococcus pneumoniae.
        Diagn Microbiol Infect Dis. 1996; 25: 201-204
        • Geddes A.M.
        Grepafloxacin-focus on respiratory infections.
        J Antimicrob. Chemother. 1997; 40: 1-4
        • Grossman R.E.
        The role of fluoroquinolones in respiratory tract infections.
        J Antimicrob Chemother. 1997; 40: 59-62

      Article info

      Publication history

      Accepted: December 18, 1998
      Received: November 18, 1998

      Footnotes

      ☆The SENTRY antimicrobial surveillance program was funded by an educational grant from Bristol-Myers Squibb Pharmaceutical Company (Princeton, NJ, USA). The European Network for Antimicrobial Resistance and Epidemiology (SNARE) received a grant (ERBCHRCT940554) from the European Union.

      Identification

      DOI: https://doi.org/10.1016/S1201-9712(99)90037-1

      Copyright

      © 1999 Published by Elsevier Inc.

      User license

      Elsevier user license |
      How you can reuse Information Icon
      Elsevier user license

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Text & data mine
      • Translate the article

      Not Permitted

      • Reuse portions or extracts from the article in other works
      • Redistribute or republish the final article
      • Sell or re-use for commercial purposes

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX